Xaproate ER 500 Tablet contains divalproex sodium 500 mg, an extended-release formulation used primarily in the management of epilepsy, bipolar disorder, and migraine prophylaxis. Divalproex acts by increasing brain concentrations of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, thereby stabilizing neuronal activity and reducing seizure frequency. The extended-release formulation allows for once-daily dosing, improving patient compliance and maintaining steady plasma drug levels. Indicated for the treatment of complex partial seizures, simple and complex absence seizures, and manic episodes associated with bipolar disorder, Xaproate ER 500 is also effective in preventing migraine headaches. The medication should be administered under medical supervision, with dosage tailored to individual patient response and tolerability. Common adverse effects include gastrointestinal disturbances, dizziness, tremor, and weight gain, while rare but serious risks involve hepatotoxicity, pancreatitis, and teratogenicity. Regular monitoring of liver function tests, complete blood counts, and serum valproate levels is recommended during therapy. Caution is advised in patients with hepatic impairment, mitochondrial disorders, and women of childbearing potential due to the risk of fetal malformations. Xaproate ER 500 Tablet provides a reliable therapeutic option for long-term management of neurological and psychiatric conditions requiring mood stabilization and seizure control.